Denali Therapeutics (DNLI) Operating Expenses (2017 - 2024)
Historic Operating Expenses for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to $129.8 million.
- Denali Therapeutics' Operating Expenses fell 205.62% to $129.8 million in Q4 2024 from the same period last year, while for Sep 2025 it was $129.8 million, marking a year-over-year decrease of 7426.77%. This contributed to the annual value of $501.9 million for FY2024, which is 480.85% down from last year.
- As of Q4 2024, Denali Therapeutics' Operating Expenses stood at $129.8 million, which was down 205.62% from $123.2 million recorded in Q3 2024.
- Over the past 5 years, Denali Therapeutics' Operating Expenses peaked at $156.0 million during Q1 2023, and registered a low of $63.6 million during Q1 2020.
- In the last 5 years, Denali Therapeutics' Operating Expenses had a median value of $112.5 million in 2022 and averaged $104.8 million.
- In the last 5 years, Denali Therapeutics' Operating Expenses skyrocketed by 4355.43% in 2023 and then plummeted by 1519.92% in 2024.
- Quarter analysis of 5 years shows Denali Therapeutics' Operating Expenses stood at $72.7 million in 2020, then rose by 23.23% to $89.6 million in 2021, then rose by 29.0% to $115.6 million in 2022, then rose by 14.65% to $132.6 million in 2023, then dropped by 2.06% to $129.8 million in 2024.
- Its Operating Expenses stands at $129.8 million for Q4 2024, versus $123.2 million for Q3 2024 and $116.6 million for Q2 2024.